Cancer biotech files for $35M IPO; Nordic Nanovector raises cash;

@FierceBiotech: Navitor grabs a $23.5M A round to tackle a key crossroad for disease. More | Follow @FierceBiotech

@JohnCFierce: Man, that Burrill lawsuit makes for interesting reading. Story | Follow @JohnCFierce

@DamianFierce: J&J Innovation's summer class of biotechs targets obesity, insomnia, heart failure, cancer and more. News | Follow @DamianFierce

> The Israeli cancer biotech Silenseed has filed plans to raise $35 million in an IPO on Nasdaq. Story

> Norway's Nordic Nanovector says it has raised NOK 250 million in a pre-IPO raise. Release

> The cancer diagnostics company Signal Genetics has raised $9 million through the sale of shares. Story

Medical Device News

@FierceMedDev: EnteroMedics up in early trading after mixed FDA panel vote. More | Follow @FierceMedDev

@StacyALawrence: Medtronic merger could give Covidien execs an $80M payout. Story | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: Single gene mutations that lower triglyceride levels could spur the development of a new class of heart disease drugs. Article | Follow @EmilyWFierce

> Data: Medtronic personalized defibrillator safer, cheaper. More

> Covidien endovascular unit could be target for cuts after Medtronic merger. Story

> Covidien recalls potentially faulty Hydrofinity guidewire. Article

Pharma News

@FiercePharma: Now out: This week's issue of FierceVaccinesWeekly report | Follow @FiercePharma

@TracyStaton: Trending now at FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. | Follow @EricPFierce

@CarlyHFierce: Czech scientists have a Lyme disease vaccine ready for animal use. A few of my favorite things in here, and Lyme disease isn't one of them. Story | Follow @CarlyHFierce

> J&J Innovation spotlights its slate of new biotech deals. Item

> Want a Big Pharma job? Apply in an emerging market--or think smaller. More

> Study: Suicides rise in wake of 'black box' warnings on antidepressants. Article

Vaccines News

> Merck, Sanofi JV wins anal cancer indication for Gardasil in EU. Story

> Themis Chikungunya prophylactic hits Phase I goal. More

> Pfizer puts the heat on Novartis with FDA MenB filing. Article

> Novartis submits Bexsero to FDA in race for MenB market. News

> MenB survivors call for Bexsero coverage in Australia. Item

> Novartis facility grabs FDA license to produce cell-culture vaccines. Report

Pharma Manufacturing News

> EMA GMP inspectors working group making updates for this year. Item

> Ranbaxy's FDA problems stymie launch of generic Nexium and the relief it would bring to consumers. More

> Dr. Reddy's initiates 2 recalls even as it invests to remove human error. Story

> Grifols doubles capacity with new U.S. plasma fractionation plant. Article

> Counterfeit antibiotics feed drug resistance, superbugs. News

> FDA finds fault with Chinese API maker. Report

Suggested Articles

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.

The biotech is pausing enrollment in some infectious and rare disease trials while continuing to try to add patients to its cancer studies.